---
title: "Mangoceuticals Delays Annual 10-K Yearly Filing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281282223.md"
description: "Mangoceuticals, Inc. (MGRX) has announced a delay in filing its Form 10-K for the fiscal year ending December 31, 2025, originally due on March 31, 2026. The delay is due to the external auditor needing more time for review. The company expects to file the report within 15 days of the original deadline and does not anticipate significant changes in its financial results. CEO Jacob D. Cohen signed the notification, emphasizing management's commitment to compliance and timely reporting."
datetime: "2026-04-01T01:41:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281282223.md)
  - [en](https://longbridge.com/en/news/281282223.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281282223.md)
---

# Mangoceuticals Delays Annual 10-K Yearly Filing

Mangoceuticals, Inc. ( (MGRX) ) has released a notification of late filing.

### End of Quarter Sale - 50% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Mangoceuticals, Inc. has notified investors that it will be late in filing its Form 10-K (Yearly Report) for the financial year ended December 31, 2025, via a Form 12b-25. The delayed filing concerns its annual report with the U.S. securities regulator, which was originally due on March 31, 2026.

The company attributes the delay mainly to its external auditor needing additional time to complete the review of the Form 10-K (Yearly Report). Management indicates it is working diligently with the auditor to finish the necessary procedures and finalize the annual report.

Under the extension rules, Mangoceuticals expects to file the Form 10-K (Yearly Report) no later than 15 calendar days after the original due date. That timetable would keep the company within the permitted grace period and limit the risk of any compliance escalation from the delay itself.

Mangoceuticals does not anticipate any significant change in its results of operations compared with the prior fiscal year once the earnings statements are filed. Investors should still treat all comments about expected timing and future results as forward-looking statements that may be affected by audit progress and other uncertainties.

The company emphasizes its intention to remain current with its reporting obligations and confirms that all other required periodic filings over the past 12 months have been submitted. The notification was signed on March 31, 2026, by Chief Executive Officer Jacob D. Cohen, underscoring executive-level oversight of the delayed filing and remediation efforts.

**More about Mangoceuticals, Inc.**

**Average Trading Volume:** 12,820,032

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $6.97M

For an in-depth examination of MGRX stock, go to TipRanks’ Overview page.

### Related Stocks

- [MGRX.US](https://longbridge.com/en/quote/MGRX.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)
- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)
- [Regenxbio's muscle disorder therapy meets main goal in late-stage study](https://longbridge.com/en/news/286406339.md)
- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)